Several studies have supported the adverse effect of mutated IGLL5, such as the pathogenesis of MM (24) and Burkitt lymphoma (30), IGH translocations in CLL (25), and association with R/R DLBCL (23). This evidence concerns the gene IGLL5 and B-cell chronic lymphocytic leukemia.